ANDOVER, Mass., May 1, 2023 /PRNewswire/ — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2023 . Recent Highlights Net revenue of $41.6…Read More
TransMedics Group Inc TransMedics Reports First Quarter 2023 Financial Results
